Effect of RANTES gene promoter genotypes in patients with ulcerative colitis

Tahara,Tomomitsu; Shibata,Tomoyuki; Okubo,Masaaki; Ishizuka,Takamitsu; Kawamura,Tomohiko; Yamashita,Hiromi; Nakamura,Masakatsu; Nakagawa,Yoshihito; Nagasaka,Mitsuo; Arisawa,Tomiyasu; Ohmiya,Naoki; Hirata,Ichiro

doi:10.3892/br.2014.287

Effect of RANTES gene promoter genotypes in patients with ulcerative colitis

Authors:
- Tomomitsu Tahara
- Tomoyuki Shibata
- Masaaki Okubo
- Takamitsu Ishizuka
- Tomohiko Kawamura
- Hiromi Yamashita
- Masakatsu Nakamura
- Yoshihito Nakagawa
- Mitsuo Nagasaka
- Tomiyasu Arisawa
- Naoki Ohmiya
- Ichiro Hirata
View Affiliations

Affiliations: Department of Gastroenterology, Fujita Health University School of Medicine, Toyoake, Aichi 470‑1192, Japan, Department of Gastroenterology, Kanzawa Medical University, Uchinada‑machi, Ishikawa 920-0293, Japan
Published online on: May 21, 2014 https://doi.org/10.3892/br.2014.287
Pages: 602-606

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

A complex interaction of genetic and environmental factors is closely associated with the development of inflammatory bowel disease. Previous studies reported that the expression of the regulated upon activation, normal T?cell expressed and secreted (RANTES) gene is enhanced in the colonic mucosa of ulcerative colitis (UC). Quantitative differences in RANTES gene expression among numerous promoter genotypes have also been reported. The aim of the present study was to clarify the effect of RANTES promoter polymorphism on the risk of UC, including its clinical phenotypes. A total of 150 UC patients and 372 healthy control (HC) subjects participated in the study. The UC patients were classified by disease behavior, severity and extent of disease. Restriction fragment length polymorphism analysis was performed for polymorphisms at ?28 C/G in the RANTES gene promoter region. Although no significant difference of the RANTES promoter genotype distribution was observed between the HC and UC groups, the G/G genotype was significantly higher among female (OR=3.95, 95% CI=1.22?12.82, P=0.03), non?steroid dependent (OR=3.37, 95% CI=1.16?9.85, P=0.03) and non?refractory (OR=3.76, 95% CI=1.29?10.98, P=0.02) UC patients. The G carrier was also found to be associated with an increased risk of rectal colitis (OR=2.21, 95% CI=1.12?4.39, P=0.03). The data indicate that the polymorphism of the RANTES promoter is not directly associated with the susceptibility to UC, but the ?28 G allele is associated with female UC patients and mild clinical phenotypes of UC, including non?steroid dependency, non?refractory and rectal colitis.

View Figures

View References

1	Head KA and Jurenka JS: Inflammatory bowel disease Part I: ulcerative colitis - pathophysiology and conventional and alternative treatment options. Altern Med Rev. 8:247–283. 2003.PubMed/NCBI
2	Lakatos L and Lakatos PL: Etiopathogenesis of inflammatory bowel diseases. Orv Hetil. 144:1853–1860. 2003.(In Hungarian).
3	Hugot JP: Inflammatory bowel disease: causes and consequences. Best Pract Res Clin Gastroenterol. 18:447–479. 2004. View Article : Google Scholar : PubMed/NCBI
4	Hugot JP and Thomas G: Genome-wide scanning in inflammatory bowel diseases. Dig Dis. 16:364–369. 1998. View Article : Google Scholar : PubMed/NCBI
5	Annese V, Valvano MR, Palmieri O, Latiano A, Bossa F and Andriulli A: Multidrug resistance 1 gene in inflammatory bowel disease: a meta-analysis. World J Gastroenterol. 12:3636–3644. 2006.PubMed/NCBI
6	Jiang Y, Xia B, Jiang L, Lv M, Guo Q, Chen M, Li J, Xia HH and Wong BC: Association of CTLA-4 gene microsatellite polymorphism with ulcerative colitis in Chinese patients. Inflamm Bowel Dis. 12:369–373. 2006. View Article : Google Scholar : PubMed/NCBI
7	Castro-Santos P, Suarez A, López-Rivas L, Mozo L and Gutierrez C: TNFalpha and IL-10 gene polymorphisms in inflammatory bowel disease. Association of −1082 AA low producer IL-10 genotype with steroid dependency. Am J Gastroenterol. 101:1039–1047. 2006.
8	Pierik M, Joossens S, Van Steen K, Van Schuerbeek N, Vlietinck R, Rutgeerts P and Vermeire S: Toll-like receptor-1, -2, and -6 polymorphisms influence disease extension in inflammatory bowel diseases. Inflamm Bowel Dis. 12:1–8. 2006. View Article : Google Scholar : PubMed/NCBI
9	Takagawa T, Tamura K, Takeda N, Tomita T, Ohda Y, Fukunaga K, Hida N, Ohnishi K, Hori K, Kosaka T, Fukuda Y, Ikeuchi H, Yamamura T, Miwa H and Matsumoto T: Association between IL-18 gene promoter polymorphisms and inflammatory bowel disease in a Japanese population. Inflamm Bowel Dis. 11:1038–1043. 2005. View Article : Google Scholar : PubMed/NCBI
10	Török HP, Glas J, Tonenchi L, Mussack T and Folwaczny C: Polymorphisms of the lipopolysaccharide-signaling complex in inflammatory bowel disease: association of a mutation in the Toll-like receptor 4 gene with ulcerative colitis. Clin Immunol. 112:85–91. 2004.PubMed/NCBI
11	Obana N, Takahashi S, Kinouchi Y, Negoro K, Takagi S, Hiwatashi N and Shimosegawa T: Ulcerative colitis is associated with a promoter polymorphism of lipopolysaccharide receptor gene, CD14. Scand J Gastroenterol. 37:699–704. 2002. View Article : Google Scholar : PubMed/NCBI
12	Schall TJ, Bacon K, Toy KJ and Goeddel DV: Selective attraction of monocytes and T lymphocytes of the memory phenotype by cytokine RANTES. Nature. 347:669–671. 1990. View Article : Google Scholar : PubMed/NCBI
13	McCormack G, Moriarty D, O’Donoghue DP, McCormick PA, Sheahan K and Baird AW: Tissue cytokine and chemokine expression in inflammatory bowel disease. Inflamm Res. 50:491–495. 2001. View Article : Google Scholar : PubMed/NCBI
14	Ansari N, Abdulla J, Zayyani N, Brahmi U, Taha S and Satir AA: Comparison of RANTES expression in Crohn’s disease and ulcerative colitis: an aid in the differential diagnosis? J Clin Pathol. 59:1066–1072. 2006.PubMed/NCBI
15	Fägerstam JP, Whiss PA, Ström M and Andersson RG: Expression of platelet P-selectin and detection of soluble P-selectin, NPY and RANTES in patients with inflammatory bowel disease. Inflamm Res. 49:466–472. 2000.PubMed/NCBI
16	Hizawa N, Yamaguchi E, Konno S, Tanino Y, Jinushi E and Nishimura M: A functional polymorphism in the RANTES gene promoter is associated with the development of late-onset asthma. Am J Respir Crit Care Med. 166:686–690. 2002. View Article : Google Scholar : PubMed/NCBI
17	Nakajima K, Tanaka Y, Nomiyama T, Ogihara T, Ikeda F, Kanno R, Iwashita N, Sakai K, Watada H, Onuma T and Kawamori R: RANTES promoter genotype is associated with diabetic nephropathy in type 2 diabetic subjects. Diabetes Care. 26:892–898. 2003. View Article : Google Scholar : PubMed/NCBI
18	Nickel RG, Casolaro V, Wahn U, Beyer K, Barnes KC, Plunkett BS, Freidhoff LR, Sengler C, Plitt JR, Schleimer RP, Caraballo L, Naidu RP, Levett PN, Beaty TH and Huang SK: Atopic dermatitis is associated with a functional mutation in the promoter of the C-C chemokine RANTES. J Immunol. 164:1612–1616. 2000. View Article : Google Scholar : PubMed/NCBI
19	Liu H, Chao D, Nakayama EE, Taguchi H, Goto M, Xin X, Takamatsu JK, Saito H, Ishikawa Y, Akaza T, Juji T, Takebe Y, Ohishi T, Fukutake K, Maruyama Y, Yashiki S, Sonoda S, Nakamura T, Nagai Y, Iwamoto A and Shioda T: Polymorphism in RANTES chemokine promoter affects HIV-1 disease progression. Proc Natl Acad Sci USA. 96:4581–4585. 1999. View Article : Google Scholar : PubMed/NCBI
20	McDermott DH, Beecroft MJ, Kleeberger CA, Al-Sharif FM, Ollier WE, Zimmerman PA, Boatin BA, Leitman SF, Detels R, Hajeer AH and Murphy PM: Chemokine RANTES promoter polymorphism affects risk of both HIV infection and disease progression in the Multicenter AIDS Cohort Study. AIDS. 14:2671–2678. 2000. View Article : Google Scholar : PubMed/NCBI
21	Podolsky DK: Inflammatory bowel disease (2). N Engl J Med. 325:1008–1016. 1991. View Article : Google Scholar : PubMed/NCBI
22	Langholz E, Munkholm P, Davidsen M and Binder V: Course of ulcerative colitis: analysis of changes in disease activity over years. Gastroenterology. 107:3–11. 1994.PubMed/NCBI
23	Locati M, Deuschle U, Massardi ML, Martinez FO, Sironi M, Sozzani S, Bartfai T and Mantovani A: Analysis of the gene expression profile activated by the CC chemokine ligand 5/RANTES and by lipopolysaccharide in human monocytes. J Immunol. 168:3557–3562. 2002. View Article : Google Scholar : PubMed/NCBI
24	Moriuchi H, Moriuchi M and Fauci AS: Nuclear factor-kappa B potently up-regulates the promoter activity of RANTES, a chemokine that blocks HIV infection. J Immunol. 158:3483–3491. 1997.PubMed/NCBI
25	al Sharif F, Ollier WE and Hajeer AH: A rare polymorphism at position −28 in the human RANTES promoter. Eur J Immunogenet. 26:373–374. 1999.